MedTrace Logo

Effect of Silymarin in Metastatic Colorectal Cancer Patients

NCT05631041 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2023-12-22

No results posted yet for this study

Summary

this work is aim to assess the antitumor effect of silymarin in patients with metastatic colorectal cancer receiving chemotherapy with or without target therapy (Bevacizumab).

Conditions

Interventions

DRUG

Silymarin

participants in silymarin group will receive silymarin 140 mg once daily.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • shimaa yassin, pharmacist · Tanta University

  • Tarek Mostafa, professor · Tanta University

  • Sahar Elhaggar, professor · Tanta University

  • Mohammed Alam El-Din, professor · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-31
Primary Completion
2024-11-30
Completion
2024-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05631041 on ClinicalTrials.gov